Invesaro

Stocks Comparison

Boston Scientific vs Dexcom: revenue, profit, margins and growth compared

Boston Scientific brought in $20.1B of revenue in fiscal 2025, Dexcom $4.7B in fiscal 2025. Revenue changed by +19.9% at Boston Scientific and +15.6% at Dexcom on the year before, so Boston Scientific grew faster. Boston Scientific kept 14.4% of its revenue as net profit, Dexcom 17.9%. Free cash flow was $3.7B at Boston Scientific and $1.1B at Dexcom.

Side by side, latest fiscal year

BSXDXCM
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$20.1B$4.7B
Revenue growth+19.9%+15.6%
Net income$2.9B$836.3M
Net margin14.4%17.9%
Free cash flow$3.7B$1.1B
Free cash flow margin18.2%23.1%
Earnings per share (diluted)$1.94$2.09
Cash$2B$917.7M
Debt$11.1Bn/a
Price to earnings22.641.4
Market value$63.7B$32.7B
Dividend yieldn/an/a
Rank by revenue in sector#30 of 523 · Health care#65 of 523 · Health care

Over the years

Revenue
BSX FY2018: $9.8BBSX FY2019: $10.7BBSX FY2020: $9.9BBSX FY2021: $11.9BBSX FY2022: $12.7BBSX FY2023: $14.2BBSX FY2024: $16.7BBSX FY2025: $20.1BDXCM FY2018: $1BDXCM FY2019: $1.5BDXCM FY2020: $1.9BDXCM FY2021: $2.4BDXCM FY2022: $2.9BDXCM FY2023: $3.6BDXCM FY2024: $4BDXCM FY2025: $4.7BFY18FY19FY20FY21FY22FY23FY24FY25
BSX $20.1BDXCM $4.7B
Net income
BSX FY2018: $1.7BBSX FY2019: $4.7BBSX FY2020: -$115MBSX FY2021: $985MBSX FY2022: $642MBSX FY2023: $1.6BBSX FY2024: $1.9BBSX FY2025: $2.9BDXCM FY2018: -$127.1MDXCM FY2019: $101.1MDXCM FY2020: $549.7MDXCM FY2021: $216.9MDXCM FY2022: $341.2MDXCM FY2023: $541.5MDXCM FY2024: $576.2MDXCM FY2025: $836.3MFY18FY19FY20FY21FY22FY23FY24FY25
BSX $2.9BDXCM $836.3M
Net margin
BSX FY2018: 17.0%BSX FY2019: 43.8%BSX FY2020: -1.2%BSX FY2021: 8.3%BSX FY2022: 5.1%BSX FY2023: 11.0%BSX FY2024: 11.1%BSX FY2025: 14.4%DXCM FY2018: -12.3%DXCM FY2019: 6.8%DXCM FY2020: 28.5%DXCM FY2021: 8.9%DXCM FY2022: 11.7%DXCM FY2023: 14.9%DXCM FY2024: 14.3%DXCM FY2025: 17.9%FY18FY19FY20FY21FY22FY23FY24FY25
BSX 14.4%DXCM 17.9%
Revenue growth
BSX FY2019: +9.3%BSX FY2020: -7.7%BSX FY2021: +19.9%BSX FY2022: +6.7%BSX FY2023: +12.3%BSX FY2024: +17.6%BSX FY2025: +19.9%DXCM FY2019: +43.1%DXCM FY2020: +30.5%DXCM FY2021: +27.1%DXCM FY2022: +18.8%DXCM FY2023: +24.5%DXCM FY2024: +11.3%DXCM FY2025: +15.6%FY19FY20FY21FY22FY23FY24FY25
BSX +19.9%DXCM +15.6%
Free cash flow
BSX FY2018: -$6MBSX FY2019: $1.4BBSX FY2020: $1.1BBSX FY2021: $1.3BBSX FY2022: $938MBSX FY2023: $1.8BBSX FY2024: $2.6BBSX FY2025: $3.7BDXCM FY2018: $56.1MDXCM FY2019: $134.5MDXCM FY2020: $276.6MDXCM FY2021: $53.3MDXCM FY2022: $304.7MDXCM FY2023: $511.9MDXCM FY2024: $630.7MDXCM FY2025: $1.1BFY18FY19FY20FY21FY22FY23FY24FY25
BSX $3.7BDXCM $1.1B

Fiscal years as each company reports them; the two may end in different months.

Questions about Boston Scientific and Dexcom

Which is bigger by revenue, Boston Scientific or Dexcom?

Boston Scientific is bigger by revenue: $20.1B in fiscal 2025, against $4.7B for Dexcom in fiscal 2025.

Which keeps more of its revenue as profit, Boston Scientific or Dexcom?

Boston Scientific had a net margin of 14.4% in fiscal 2025; Dexcom had 17.9% in fiscal 2025.

Which grew revenue faster, Boston Scientific or Dexcom?

In their latest fiscal years revenue changed by +19.9% at Boston Scientific and +15.6% at Dexcom.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies